Expression and significance of SHP-2 in human papillomavirus infected cervical cancer

Abstract

This study investigated the expression and prognostic value of SHP-2 in cervical cancer caused by human papillomavirus (HPV) infection. Forty-five specimens from patients with cervical cancer (stage I–III), 32 specimens from patients with cervical intraepithelial neoplasia (CIN) (I, II) and 20 normal cervical samples from patients with hysteromyoma were collected in Department of Pathology for comparison. The expression levels of SHP-2 and IFN-β proteins were detected by using immunohistochemistry. The mRNA expression level of SHP-2 was detected by using quantitative real-time polymerase chain reaction (PCR). HPVs were detected by HPV GenoArray Test. The Spearman correlation was used to compare the expression level of SHP-2 in HPV infected cervical cancer vs non-HPV infected normal cervix. The level of SHP-2 protein expression in the cancer tissues (88.8%) was significantly higher than in CIN tissues (62.5%) and normal cervixes (45%) (P<0.05 and P<0.05, respectively). The SHP-2 mRNA levels in the cancer tissues were upregulated as compared with those in the normal cervixes (P<0.05). Twenty-one (46.7%) cervical cancers, 25 (78.1%) CINs and 17 (85%) normal cervixes showed IFN-β positive staining in cytoplasm. There was statistically significant difference in the expression rate of IFN-β between cervical cancer and normal cervix (χ²=8.378, P<0.05) as well as between cervical cancer and CIN (χ²=7.695, P<0.05). HPV16/18 infections could be found in normal cervixs (15%), CINs (68.7%) and cervical cancers (84.4%). There was a correlation between HPV infection and SHP-2 expression in cervical cancer (r_s=0.653, P<0.05). SHP-2 may be a useful prognostic and diagnostic indicator for HPV infected cervical cancer. In cervical cancers, SHP-2 mRNA and protein overexpression was associated with IFN-β lower-expression.

Keywords

cervical cancer / cervical intraepithelial neoplasia / human papillomavirus / SH2-containing protein tyrosine phosphatase 2 / type I interferon β

References

[1] MatthewsR.J., BowneD.B., FloresE., et al.. Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences. Mol Cell Biol, 1992, 12(5): 2396-2405

[2] NeelB.G., GuH., PaoL.. The ’shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem, 2003, 28(6): 284-293

[3] KharitonenkovA., ChenZ., SuresI., et al.. A family of proteins that inhibit signaling through tyrosine kinase receptors. Nature, 1997, 386(6621): 181-186

[4] BennettA.M., TangT.L., SugimotoS., et al.. Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc Natl Acad, 1994, 91(15): 7335-7339

[5] QuC.K.. The SHP-2 tyrosine phosphatase: Signaling mechanisms and biological functions. Cell Res, 2000, 10(4): 279-288

[6] YouM., FlickL.M., YuD., et al.. Modulation of the nuclear factor kappa B pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor. J Exp Med, 2001, 193(1): 101-110

[7] WalboomersJ.M., JacobsM.V., ManosM.M., et al.. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999, 189(1): 12-19

[8] BryanJ.T.. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine, 2007, 25(16): 3001-3006

[9] LeeK.M., ChuangE., GriffinM., et al.. Molecular basis of T cell inactivation by CTLA-4. Science, 1998, 282(5397): 2263-2266

[10] YuW.M., HawleyT.S., HawleyR.G., et al.. Catalytic-dependent and independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling. Oncogene, 2003, 22(38): 5995-6004

[11] HuangQ., Lerner-MarmaroshN., CheW., et al.. The novel role of the C-terminal region of SHP-2 involvement of Gab1 and SHP-2 phosphatase activity in Elk-1 activation. J Biol Chem, 2002, 277(32): 29 330-29 341

[12] AhmadS., BanvilleD., ZhaoZ., et al.. A widely expressed human protein-tyrosine phosphatase containing src homology 2 domains. Proc Natl Acad, 1993, 90(6): 2197-2201

[13] FengG.S., HuiC.C., PawsonT.. SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases. Science, 1993, 259(5101): 1607-1611

[14] VogelW., LammersR., HuangJ., et al.. Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science, 1993, 259(5101): 1611-1614

[15] KeY., ZhangE.E., HagiharaK., et al.. Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality. Mol Cell Biol, 2007, 27(19): 6706-6717

[16] VoenaC., ConteC., AmbrogioC., et al.. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res, 2007, 67(9): 4278-4286

[17] XuR.. Shp-2, a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia. Cell Res, 2007, 17(4): 295-297

[18] HaoX.P., PretlowT.G., RaoJ.S., et al.. Beta-catenin expression is altered in human colonic aberrant crypt foci. Cancer Res, 2001, 61(22): 8085-8088

[19] JarboeJ.S., JohnsonK.R., ChoiY., et al.. Expression of interleukin-13 receptor α2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res, 2007, 67(17): 7983-7986

[20] AnH.Z., ZhaoW., HouJ., et al.. SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production. Immunity, 2006, 25(6): 919-928

[21] FitzgeraldK.A., McWhirterS.M., FaiaK.L., et al.. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol, 2003, 4(5): 491-496

[22] WangY., ChenT., HanC.. Lysosome-associated small Rab GTPase Rab7b negatively regulates TLR4 signaling in macrophages by promoting lysosomal degradation of TLR4. Blood, 2007, 110(3): 962-971

[23] TakedaK., KaishoT., AkiraS.. Toll-like receptors. Annu Rev Immunol, 2003, 21(1): 335-376

[24] YouM., FlickL.M., YuD., et al.. Modulation of the nuclear factor kappa B pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor. J Exp Med, 2001, 193(1): 101-110

[25] DuZ., ShenY., YangW., et al.. Inhibition of IFN-a signaling by a PKC- and protein tyrosine phosphatase SHP-2-dependent pathway. Proc Natl Acad, 2005, 102(29): 10 267-10 272

[26] YouM., YuD.H., FengG.S.. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated JAK/STAT pathway. Mol Cell Biol, 1999, 19(3): 2416-2424

[27] HongF., NguyenV.A., GaoB.. Tumor necrosis factor α attenuates interferon α signaling in the liver: involvement of SOCS3 and SHP2 and implication in resistance to interferon therapy. FASEB J, 2001, 15(9): 1595-1597